TScan Therapeutics Announces $30 Million Registered Direct OfferingOn December 26, 2024, TScan Therapeutics, Inc. (NASDAQ: TCRX) entered into a securities purchase agreement with Lynx1 Capital Management LP, an existing shareholder, and an investment
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read TScan Therapeutics’s 8K filing here. TScan Therapeutics Company Profile (Get Free Report) TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients […]
More Stories
A New Dawn for Venezuela: How the Capture of Nicolás Maduro Paves the Way for Prosperity, Justice, and Global Stability
By Stephen Zogopoulos, USNN World News In a bold and decisive move that has reshaped the geopolitical landscape of the...
With GDP up 4.3%, 5% Gains Are Likely in 2026
By Louis Navellier Commentary My 5% GDP growth prediction raised some eyebrows during a recent appearance on Fox Business News. However,...
After Maduro’s Arrest, CCP Censors Let Anti-American Hatred Spread Online—By Design: Analysts
By Michael Zhuang News Analysis After U.S. special forces captured Venezuelan leader Nicolás Maduro to stand trial in federal court,...
The Truth About Venezuela Under Socialism, From Those Who Fled It
By Troy Myers DORAL, Fla.—Zarai Maza survived a torched vehicle and a horrific car crash after peacefully protesting the Venezuelan...
DOJ Sues Arizona, Connecticut for Failing to Hand Over Voter Rolls
By Matthew Vadum The U.S. Department of Justice (DOJ) said on Jan. 6 that it is suing Arizona and Connecticut...
US Discusses Ways to Acquire Greenland; Military Use on Table
By Kimberly Hayek President Donald Trump is seeking to acquire Greenland as a U.S. national security priority necessary to deter...